Association between plasma docosahexaenoic acid levels and the incidence of frailty: A prospective analysis of the UK Biobank.
Key claim: Higher plasma docosahexaenoic acid (DHA) levels were prospectively associated with an 18% reduced risk of incident frailty in adults over nearly a decade of follow-up.
Abstract
OBJECTIVES: The blood level of n-3 polyunsaturated fatty acids (PUFAs) has been associated cross-sectionally with frailty, but its relationship with incident frailty remains unclear. The present study investigates the hypothesis that plasma levels of n-3 PUFAs, particularly docosahexaenoic acid (DHA), are inversely associated with the incidence of frailty and individual frailty criteria. DESIGN: Prospective cohort study. SETTING: The UK Biobank cohort. PARTICIPANTS: A total of 38,577 non-frail adults aged 40-69 years who enrolled between 2006 and 2010 were followed for a maximum of 13 years. MEASUREMENTS: Frailty was defined as meeting at least 3 of 5 separate criteria (low physical activity, exhaustion, slow walking speed, weight loss, and low grip strength), and plasma levels of total n-3 PUFAs, DHA, and non-DHA n-3 PUFAs were measured by nuclear magnetic resonance. Cox-proportional hazards models were used to predict incident frailty after adjusting for demographic, medical history and other potential confounding factors. RESULTS: After a median follow-up of 9.37 years, 1,024 individuals became frail. The incidence of frailty was inversely associated with plasma level of DHA (hazard ratio [HR] per inter-quintile range: 0.82, 95% confidence interval [CI] 0.69-0.97; p=0.019) after adjusting for confounding factors. Plasma level of DHA was inversely associated with the incidence of two frailty criteria-low physical activity and exhaustion. On the other hand, neither plasma levels of non-DHA n-3 PUFAs (HR 0.98, 95% CI 0.83-1.16) nor those of total n-3 PUFAs (HR 0.91, 95% CI 0.77-1.07) was significantly associated with the incidence of frailty after adjusting for confounding factors. CONCLUSIONS: The incidence of frailty was inversely associated with the plasma level of DHA but not with the levels of other n-3 PUFAs, suggesting that a low plasma DHA level could help identify individuals at high risk for developing frailty, enabling preventive measures to be initiated.
Why this matters
This human-observational finding adds long-term frailty evidence to an omega-3 page currently framed around expert opinion on brain health. The reported DHA-specific association distinguishes circulating fatty-acid measures rather than establishing a benefit for omega-3 supplements as a class, and it does not demonstrate causation or address dementia outcomes.